Cargando…

Impact of TP53 mutations in Triple Negative Breast Cancer

Identifying triple negative breast cancer (TNBC) patients expected to have poor outcomes provides an opportunity to enhance clinical management. We applied an Evolutionary Action Score to functionally characterize TP53 mutations (EAp53) in 96 TNBC patients and observed that EAp53 stratification may...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mitri, Zahi I., Abuhadra, Nour, Goodyear, Shaun M., Hobbs, Evthokia A., Kaempf, Andy, Thompson, Alastair M., Moulder, Stacy L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Brief Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9463132/ https://www.ncbi.nlm.nih.gov/pubmed/36085319 http://dx.doi.org/10.1038/s41698-022-00303-6

Ejemplares similares

Real-World Evaluation of Disease Progression After CDK 4/6 Inhibitor Therapy in Patients With Hormone Receptor-Positive Metastatic Breast Cancer
por: West, Malinda T, et al.
Publicado: (2023)

Early-stage Triple-negative Breast Cancer: Time to Optimize Personalized Strategies
por: Abuhadra, Nour, et al.
Publicado: (2022)

Multimodality MRI radiomics analysis of TP53 mutations in triple negative breast cancer
por: Sun, Kun, et al.
Publicado: (2023)

Somatic intronic TP53 c.375+5G mutations are a recurrent but under‐recognized mode of TP53 inactivation
por: Chui, M Herman, et al.
Publicado: (2021)

Prognostic significance of CD117 expression and TP53 missense mutations in triple-negative breast cancer
por: Luo, Yanli, et al.
Publicado: (2018)

Association between Mutation and Expression of TP53 as a Potential Prognostic Marker of Triple-Negative Breast Cancer
por: Kim, Ji-Yeon, et al.
Publicado: (2016)

TP53 mutations detected in circulating tumor cells present in the blood of metastatic triple negative breast cancer patients
por: Fernandez, Sandra V, et al.
Publicado: (2014)

The TP53 website: an integrative resource centre for the TP53 mutation database and TP53 mutant analysis
por: Leroy, Bernard, et al.
Publicado: (2013)

Polymorphisms in Apoptosis-Related Genes and TP53 Mutations in Non-Small Cell Lung Cancer
por: Bae, Eun Young, et al.
Publicado: (2011)

Prognostic Impact of High Baseline Stromal Tumor-Infiltrating Lymphocytes in the Absence of Pathologic Complete Response in Early-Stage Triple-Negative Breast Cancer
por: Abuhadra, Nour, et al.
Publicado: (2022)

Ado-trastuzumab for the treatment of metastatic HER2-positive breast cancer in patients previously treated with Pertuzumab
por: Al Rabadi, Luai S., et al.
Publicado: (2021)

Germline TP53 and MSH6 mutations implicated in sporadic triple-negative breast cancer (TNBC): a preliminary study
por: Yi, Dandan, et al.
Publicado: (2019)

Analysis of Intrinsic Breast Cancer Subtypes: The Clinical Utility of Epigenetic Biomarkers and TP53 Mutation Status in Triple-Negative Cases
por: Sadzeviciene, Ieva, et al.
Publicado: (2022)

Limited importance of the dominant-negative effect of TP53 missense mutations
por: Stoczynska-Fidelus, Ewelina, et al.
Publicado: (2011)

Predictive Roles of Baseline Stromal Tumor-Infiltrating Lymphocytes and Ki-67 in Pathologic Complete Response in an Early-Stage Triple-Negative Breast Cancer Prospective Trial
por: Abuhadra, Nour, et al.
Publicado: (2023)

Chemokine Network and Overall Survival in TP53 Wild-Type and Mutant Ovarian Cancer
por: Ignacio, Rosa Mistica C., et al.
Publicado: (2018)

The tumor suppressor Hic1 maintains chromosomal stability independent of Tp53
por: Szczepny, Anette, et al.
Publicado: (2018)

Role of TP53 mutations in triple negative and HER2-positive breast cancer treated with neoadjuvant anthracycline/taxane-based chemotherapy
por: Darb-Esfahani, Silvia, et al.
Publicado: (2016)

TP53 Combined Phenotype Score Is Associated with the Clinical Outcome of TP53-Mutated Myelodysplastic Syndromes
por: Yabe, Mariko, et al.
Publicado: (2021)

Mitigating the Risk of t-MNs Development: TP53 or Not TP53?
por: Tesio, Melania
Publicado: (2023)

CD80 expression is upregulated by TP53 activation in human cancer epithelial cells
por: Scarpa, Melania, et al.
Publicado: (2021)

Studies of TP53 haplotypes in relation to LOH and TP53 mutations in breast cancer patients
por: Langerød, A, et al.
Publicado: (2000)

Prognostic value genotypes and LOH at TP53 codon 72 and TP53 mutations in primary breast cancer
por: Kyndi, M, et al.
Publicado: (2005)

p53 pathway dysfunction in AML: beyond TP53 mutations
por: Post, Sean M., et al.
Publicado: (2017)

The relationship of TP53 R72P polymorphism to disease outcome and TP53 mutation in myelodysplastic syndromes
por: McGraw, K L, et al.
Publicado: (2015)

Mutant TP53 modulates metastasis of triple negative breast cancer through adenosine A2b receptor signaling
por: Horigome, Eisuke, et al.
Publicado: (2018)

Co-Expression and Combined Prognostic Value of CSPG4 and PDL1 in TP53-Aberrant Triple-Negative Breast Cancer
por: Hu, Zhe-Yu, et al.
Publicado: (2022)

380 The kinesin-like protein Kif11 is essential for the survival of TP53 mutant triple-negative breast cancer cells
por: Lanier, Amanda, et al.
Publicado: (2023)

TP53_PROF: a machine learning model to predict impact of missense mutations in TP53
por: Ben-Cohen, Gil, et al.
Publicado: (2022)

Impact of TP53 mutations in breast cancer: Clinicopathological features and prognosisImpact of TP53 mutations in breast CA
por: Li, Xuerui, et al.
Publicado: (2020)

Milking the stroma in triple-negative breast cancer
por: Thompson, Alastair M., et al.
Publicado: (2012)

TP53 Alterations Are Associated With Poor Survival in Patients With Primary Mediastinal Nonseminoma Germ Cell Tumors
por: Bacon, Jack V W, et al.
Publicado: (2022)

Analysis of Tp53 Codon 72 Polymorphisms, Tp53 Mutations, and HPV Infection in Cutaneous Squamous Cell Carcinomas
por: Loeb, Keith R., et al.
Publicado: (2012)

TP53 and TP53-associated genes are correlated with the prognosis of paediatric neuroblastoma
por: Wang, Haiwei, et al.
Publicado: (2022)

Is the future of personalized therapy in triple-negative breast cancer based on molecular subtype?
por: Le Du, Fanny, et al.
Publicado: (2015)

TP 53 status and estrogen receptor-beta in triple negative breast cancer management in Africa: Time to rethink regime management of triple negative breast cancer and save more lives in Nigeria
por: Nzegwu, Martin Arinzechukwu, et al.
Publicado: (2021)

KRAS and TP53 Mutations in Colorectal Carcinoma
por: Al-Kuraya, Khawla S.
Publicado: (2009)

Adolescent triple-negative breast cancer with germline pathogenic variants in both BRCA1 and TP53 genes: A case report
por: Chen, Dongmei, et al.
Publicado: (2022)

The contribution of CHEK2 to the TP53-negative Li-Fraumeni phenotype
por: Ruijs, Marielle WG, et al.
Publicado: (2009)

Genomic landscape of TP53-mutated myeloid malignancies
por: Abel, Haley J., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_odmr64rnvn1m43dhf0ojr44lqd